Analysts Favor Selective Opportunities in Mixed U.S. Market Outlook

On Thursday, October 1, 2026, U.S. analysts provided a mixed outlook on the market, favoring company-specific opportunities over broad bullish calls. The updates included significant adjustments across various sectors, with a notable emphasis on technology hardware and software receiving higher targets, while regional banks and financial services saw cuts.

In the technology sector, Accenture (ACN) received contrasting ratings with Evercore setting a price target of $250.00 and an Outperform rating, while Jefferies reiterated a Hold rating. Apple (AAPL) saw its target lowered by Morgan Stanley to $355.00 from $360.00, maintaining an Overweight rating, while Needham kept a Hold rating. Hewlett Packard Enterprise (HPE) drew attention with multiple upgrades, including Barclays raising its target to $83.00 from $79.00 and Citigroup to $92.00 from $76.00, all maintaining positive ratings.

The energy and biotechnology sectors showed mixed signals. BP (BP) was downgraded to Neutral by BTIG and initiated with a Hold rating by Needham. In biotech, BeOne Medicines (ONC) saw its target raised by JPMorgan to $445.00 from $425.00, maintaining an Overweight rating, while AxoGen (AXGN) had its target lowered to $53.00 from $60.00 with a Buy rating.

Financial services experienced a wave of downgrades and target cuts. Bank of America (BAC) had its target lowered by Truist to $62.00 from $65.00, while Evercore set a target of $62.00. First Citizens BancShares (FCNCA) was reiterated as Neutral by Citigroup, and JPMorgan lowered its target to $2,300.00 from $2,450.00. The updates reflect a selective approach, with analysts focusing on individual company prospects rather than broader market trends.